Share-based Payment Arrangement, Expense in USD of LIXTE BIOTECHNOLOGY HOLDINGS, INC. from Q3 2015 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
LIXTE BIOTECHNOLOGY HOLDINGS, INC. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from Q3 2015 to Q3 2025.
  • LIXTE BIOTECHNOLOGY HOLDINGS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $776,611, a 627% increase year-over-year.
  • LIXTE BIOTECHNOLOGY HOLDINGS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1,222,325, a 175% increase year-over-year.
  • LIXTE BIOTECHNOLOGY HOLDINGS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $418,422, a 46% decline from 2023.
  • LIXTE BIOTECHNOLOGY HOLDINGS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $773,203, a 50% decline from 2022.
  • LIXTE BIOTECHNOLOGY HOLDINGS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $1,546,040, a 30% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

LIXTE BIOTECHNOLOGY HOLDINGS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,222,325 $776,611 +$669,784 +627% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $552,541 $267,999 +$137,308 +105% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $415,233 $99,738 -$3,189 -3.1% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $418,422 $77,977 -$26,080 -25% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $444,502 $106,827 -$5,279 -4.7% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $449,781 $130,691 -$149,369 -53% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $599,150 $102,927 -$174,053 -63% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $773,203 $104,057 -$281,334 -73% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $1,054,537 $112,106 -$284,777 -72% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $1,339,314 $280,060 -$144,034 -34% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $1,483,348 $276,980 -$62,692 -18% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $1,546,040 $385,391 +$248,502 +182% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
Q3 2022 $1,297,538 $396,883 +$49,661 +14% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $1,247,877 $424,094 -$637,043 -60% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $1,884,920 $339,672 -$316,360 -48% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $2,201,280 $136,889 +$174,738 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $2,026,542 $347,222 -$117,261 -25% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $2,143,803 $1,061,137 +$1,034,137 +3830% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $1,109,666 $656,032 +$629,032 +2330% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $480,634 $37,849 -$64,849 -240% 01 Oct 2020 31 Dec 2020 10-K 21 Mar 2022 2021 FY
Q3 2020 $545,483 $464,483 +$432,453 +1350% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $113,030 $27,000 -$296,665 -92% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $409,695 $27,000 -$12,936 -32% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q4 2019 $422,631 $27,000 -$22,222 -45% 01 Oct 2019 31 Dec 2019 10-K 26 Mar 2021 2020 FY
Q3 2019 $444,853 $32,030 -$752,360 -96% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $1,197,213 $323,665 +$323,665 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $873,548 $39,936 +$39,936 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $833,612 $49,222 +$16,228 +49% 01 Oct 2018 31 Dec 2018 10-K 25 Mar 2020 2019 FY
Q3 2018 $817,384 $784,390 +$768,430 +4815% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $48,954 $0 +$50,198 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $1,244 $0 -$71,939 -100% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $70,695 $32,994 +$39,961 01 Oct 2017 31 Dec 2017 10-K 25 Mar 2019 2018 FY
Q3 2017 $30,734 $15,960 -$129,841 -89% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $160,575 $50,198 -$228,893 -128% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $389,468 $71,939 +$102,309 01 Jan 2017 31 Mar 2017 10-Q 27 Apr 2018 2018 Q1
Q4 2016 $287,159 $6,967 01 Oct 2016 31 Dec 2016 10-K 23 Mar 2018 2017 FY
Q3 2016 $145,801 -$111,959 -43% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $178,695 01 Apr 2016 30 Jun 2016 10-Q 04 Aug 2017 2017 Q2
Q1 2016 $30,370 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q3 2015 $257,760 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016 2016 Q3

LIXTE BIOTECHNOLOGY HOLDINGS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $418,422 -$354,781 -46% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $773,203 -$772,837 -50% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $1,546,040 -$655,240 -30% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $2,201,280 +$1,720,646 +358% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $480,634 +$58,003 +14% 01 Jan 2020 31 Dec 2020 10-K 21 Mar 2022 2021 FY
2019 $422,631 -$410,981 -49% 01 Jan 2019 31 Dec 2019 10-K 26 Mar 2021 2020 FY
2018 $833,612 +$762,917 +1079% 01 Jan 2018 31 Dec 2018 10-K 25 Mar 2020 2019 FY
2017 $70,695 -$216,464 -75% 01 Jan 2017 31 Dec 2017 10-K 25 Mar 2019 2018 FY
2016 $287,159 -$262,538 -48% 01 Jan 2016 31 Dec 2016 10-K 23 Mar 2018 2017 FY
2015 $549,697 01 Jan 2015 31 Dec 2015 10-K 29 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.